Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1.

British journal of cancer - 1 May 2026

Sugitatsu Yuya, Tomida Akimasa, Suematsu Masaya, Inoue Tomoya, Kubo Hiroshi, Nakazawa Yozo, Yagyu Shigeki, Iehara Tomoko

Abstract excerpt

BACKGROUND: High-risk ALK-mutant neuroblastoma (NB) presents challenges due to drug resistance and an immunosuppressive tumour microenvironment (TME). Combining molecular targeted therapy with adoptive cell therapy offers a potential therapeutic strategy. OBJECTIVE: To investigate the effects of alectinib, an ALK inhibitor, with disialoganglioside 2 (GD2) chimeric antigen receptor T (CAR-T) cell therapy in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Gangliosides

Share to Immunotherapy, Adoptive

Share to Neuroblastoma

Share to Piperidines

Share to Receptors, Chimeric Antigen

Source

Open in PubMed Open full text

Identifiers

PMID: 41866626
DOI: 10.1038/s41416-026-03363-8
PMCID: PMC13133162

Genes

ALK
STAT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK-mutated neuroblastoma by suppressing programmed death-ligand 1.PMID 41866626Read ↗

Current Knowledge and Perspectives of Immunotherapies for NeuroblastomaSemantic proximity Read ↗

The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.Semantic proximity Read ↗

Immunotherapy of Neuroblastoma: Facts and HopesSemantic proximity Read ↗

Inhibition of autophagy enhances the antitumor efficacy of T/CAR T cell against neuroblastomaSemantic proximity Read ↗

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma CellsSemantic proximity Read ↗

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD 2 antibody ch14.18/CHOSemantic proximity Read ↗

GD2 targeting CAR T cells for neuroblastomaSemantic proximity Read ↗

Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cellsSemantic proximity Read ↗

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical ModelsSemantic proximity Read ↗

COMBINATION THERAPIES TARGETING ALK-ABERRANT NEUROBLASTOMA IN PRECLINICAL MODELSSemantic proximity Read ↗

Inhibition of MEK pathway enhances the antitumor efficacy of chimeric antigen receptor T cells against neuroblastoma.Semantic proximity Read ↗

Good clinical response to alectinib, a second generation ALK inhibitor, in refractory neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.